GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- Innovative Biosensors Inc., a privately held pioneering developer of rapid diagnostic technologies, today announced that the Company has entered into a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the development of a SARS test using the company's CANARY(TM) technology.
The agreement involves the development of a rapid, portable and highly sensitive system for the detection of SARS.
USAMRIID, located at Fort Detrick, Maryland, is the lead laboratory for the Medical Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
While the Institute's primary focus is on protecting military service members, its research programs have applications that benefit society as a whole. USAMRIID investigators actively contribute to advances in scientific knowledge and collaborate with the Centers for Disease Control and Prevention, the National Institutes of Health, the World Health Organization, the Department of Energy, the Federal Bureau of Investigation, and academic centers of excellence worldwide. USAMRIID also serves as a reference laboratory for the CDC and the WHO.
About Innovative Biosensors
Innovative Biosensors is a privately held company developing novel technologies for the rapid detection of pathogens. The Company's technology is expected to have broad applications in food testing, animal health, biodefense, and human health care, including drug discovery and development, and disease diagnosis.
Additional information is available at http://www.innovativebiosensors.com/.
This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensor's mission to develop and commercialize instrument systems, Innovative Biosensor's ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Innovative Biosensors caution investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensor's expectations that they will incur operating losses in the near future, the early stage of development of Innovative Biosensor's products and technologies, uncertainties related to preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors products, processes and technologies, Innovative Biosensor's ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
Innovative Biosensors Inc.